| Name | Title | Contact Details |
|---|
BioDuro, now a PPD company, is a leading integrated drug discovery outsourcing company that provides high-quality, integrated research and development services to meet the growing needs of the global biotechnology and pharmaceutical industries. Together, PPD and BioDuro have the expertise to perform a broad range of research and development services for pharmaceutical and biotech clients from discovery through Phase IV. Founded in 2005, BioDuro has more than 675 employees, the majority of whom are based in Beijing, where the company operates a state-of-the-art, 110,000-square-foot laboratory. BioDuro provides high-quality medicinal chemistry, discovery biology, pharmacology, synthesis, bioanalytical and drug safety evaluation services. Its discovery biology services range from reagent generation to assay development to screening and biochemistry.
Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches.
Trevena is a publicly traded clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. We have three programs in clinical development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently in phase 2 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in phase 1 testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity.
CellMax Life is revolutionizing early cancer detection, prevention and management.